Angionix Balloon for Opening Blocked Heart Arteries in Coronary Artery Disease
Follows people with coronary artery disease treated with the Angionix Balloon.
Key facts
- Who runs it
- Yonsei University
- Where
- Daegu, Jeonju, and Yongin, South KoreaSee the 3 sites
- Trial code
- Registry title
- Efficacy and Safety of the Angionix Balloon in Patients With Coronary Artery Disease Undergoing PTCA
- Status
- Not yet recruiting
- People taking part
- 600 people, planned
- Started
- 9 Nov 2026
- Expected to end
- 1 Jul 2028
- Type of study
- Observational
- Treatments tested
- Angionix Balloon
- Record updated
- 9 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with coronary artery disease who need a balloon procedure (PTCA) with the Angionix Balloon or Angionix NC Balloon.
- Age
- 19 years or older
- Sex
- Men and women can join.
- Disease stage
- Coronary artery disease that needs percutaneous transluminal coronary angioplasty (PTCA).
Main reasons for not taking part
- Cardiogenic shock, as judged by the investigator
- Vessel dissection already seen on coronary angiography before the PTCA procedure
- Pregnant or breastfeeding women
- Other significant findings that the investigator judges make taking part unsuitable
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Adult aged 19 years or older at baseline
- Patients diagnosed with coronary artery disease
- Patients requiring percutaneous transluminal coronary angioplasty (PTCA) with Angionix Balloon or Angionix NC Balloon
- Patients who voluntarily agree to participate in this study and sign an informed consent form
Who cannot take part
- Patients with vessel dissection already identified on coronary angiography prior to PTCA procedure based on the investigator's clinical judgment
- Patients presenting with cardiogenic shock based on the investigator's clinical judgment
- Pregnant or lactating women
- Patients who have other clinically significant findings that make them unsuitable for study participation based on the investigator's medical judgment
Where in South Korea
- Kyungpook National University College HospitalDaegu, South KoreaContact: Yongcheol Kim, MD.,PhDNot yet recruiting
- jeonbuk National University HospitalJeonju, South KoreaContact: Yongcheol Kim, MD.,PhDNot yet recruiting
- Yongcheol KimYongin, South KoreaContact: Yongcheol Kim, MD.,PhDNot yet recruiting
About the trial
What the trial wants to find out
A Multi-center, Registry evaluating the efficacy and safety of the use of Angionix Balloon in Patient with Coronary Artery Disease
The group in the trial
- Angionix Registry Cohort
Adult patients aged 19 years or older with coronary artery disease who require percutaneous transluminal coronary angioplasty (PTCA) using Angionix Balloon or Angionix NC Balloon.
Treatment: Angionix Balloon
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-center, Registry Evaluating the Efficacy and Safety of the Use of Angionix Balloon in Patient With Coronary Artery Disease
- Plain-language title
- Angionix Balloon for Opening Blocked Heart Arteries in Coronary Artery DiseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 9 October 2026